Stay updated with breaking news from Nasdaq ymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report)’s stock price rose 5.9% during mid-day trading on Monday . The company traded as high as $17.49 and last traded at $17.22. Approximately 119,509 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 406,738 shares. The stock had previously closed […] ....
Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research report released on Monday morning, RTT News reports. They currently have a $18.00 price objective on the stock, up from their prior price objective of $12.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.19) […] ....
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) were up 2.8% on Tuesday . The company traded as high as $12.50 and last traded at $12.45. Approximately 32,320 shares changed hands during trading, a decline of 92% from the average daily volume of 411,775 shares. The stock had previously closed at $12.11. Analysts […] ....
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The […] ....
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy […] ....